Abstracts tagged "morbidity and mortality"

Abstract Number: 1894 • 2016 ACR/ARHP Annual Meeting
Increased Mortality in Systemic Sclerosis Patients with Fibrosing Myopathy
Julie J. Paik¹, Fredrick M. Wigley², Ami A. Shah¹, Andrea Corse³, Laura K. Hummers⁴ and Andrew Mammen⁵, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ³Neurology, Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is associated with poor outcomes such as disability. The spectrum of muscle histopathology of weak SSc patients is…
Abstract Number: 3069 • 2016 ACR/ARHP Annual Meeting
Weight Loss in the Early Rheumatoid Arthritis Period Is Associated with Subsequent Increased Mortality in RA Patients and Matched Comparators: Evidence Against an RA-Specific Obesity Paradox
Jeffrey A. Sparks¹, Shun-Chiao Chang², Uyen Sa D.T. Nguyen^3,4, Medha Barbhaiya², Sara K. Tedeschi², Bing Lu², Karen H. Costenbader², Yuqing Zhang⁵, Hyon K. Choi⁶ and Elizabeth W. Karlson², ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA, ⁶Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose : Weight loss may explain the obesity paradox for mortality, since those who unintentionally lose weight to reach normal BMI may have higher mortality…
Abstract Number: 3070 • 2016 ACR/ARHP Annual Meeting
Effect of Sarcopenia, Subcutaneous Adipose Tissue and Abdominal Visceral Fat on Mortality Risk of Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study
Felipe M Santana¹, Michel A Gonçalves², Diogo S Domiciano³, Luana G Machado³, Jaqueline B Lopes³, Camille P Figueiredo³, Valéria Caparbo³, Liliam Takayama³ and Rosa M R Pereira⁴, ¹Deparment of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Department of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil
Background/Purpose: Body composition changes resulting from ageing (decreased muscle mass and increased fat tissue) are frequently not accompanied by concomitant changes in body mass index…
Abstract Number: 3171 • 2016 ACR/ARHP Annual Meeting
The Impact of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases
April Jorge, Na Lu and Hyon K. Choi, Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Individuals with systemic autoimmune rheumatic diseases (SARDs)—such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc)—have been found to have an increased risk of…
Abstract Number: 3172 • 2016 ACR/ARHP Annual Meeting
Temporal Trends in SLE Mortality According to Sex, Race, Ethnicity, and Geographic Region in the United States over the Past Five Decades
Eric Yen¹, Magda Shaheen², Jennifer MP Woo¹, Neil Mercer¹, Lewei Duan¹, Ning Li¹, Arun Karlamangla¹, Deborah K. McCurdy¹ and Ram R. Singh¹, ¹UCLA, Los Angeles, CA, ²Charles R. Drew University of Medicine and Science, Los Angeles, CO
Background/Purpose: Over the past half-century, diagnostic and therapeutic developments for SLE have led to dramatic improvements in the 5- and 10-year survival. Whether these achievements…
Abstract Number: 27 • 2016 ACR/ARHP Annual Meeting
A Rheumatologist’s Assessment of Therapy Responses (Rxresp) and Rheumatoid Factor Status (neg/pos) in 1995 Predicted Mortality through 2015 in a Community-Based Cohort of Incident Rheumatoid Arthritis Cases and Matched Control Subjects
Alfonse T. Masi¹, Azeem A. Rehman², Laura Jorgenson³ and Jean C. Aldag³, ¹University of Illinois, College of Medicine at Peoria, Peoria, IL, ²Neurosurgery, University of West Virginia Medical School, Morgantown, WV, ³Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Greater disease severity, older age, positive serum rheumatoid factor (RF), and long-standing glucocorticoid usage contribute to increased mortality of rheumatoid arthritis (RA) patients. This…
Abstract Number: 28 • 2016 ACR/ARHP Annual Meeting
Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid Arthritis (RA) Patients and Matched Non-RA (CN) Subjects
Alfonse T. Masi¹, Azeem A. Rehman², Laura Jorgenson³ and Jean C. Aldag³, ¹University of Illinois, College of Medicine at Peoria, Peoria, IL, ²Neurosurgery, University of West Virginia Medical School, Morgantown, WV, ³Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid…
Abstract Number: 523 • 2016 ACR/ARHP Annual Meeting
Mortality Profile of Patients with Rheumatoid Arthritis in France and Its Change in 10 Years
Jerome Avouac¹, Fazia Amrouche², Christophe Meune³, Grégoire Rey⁴, Andre Kahan⁵ and Yannick Allanore⁶, ¹Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Paris Descartes University, Cochin Hospital, Paris, France, ³Cardiology department, Université Paris XIII, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Bobigny, France, ⁴Inserm-CépiDc, Hospital Bicêtre, Le Kremlin-Bicêtre, France, ⁵Service de Rhumatologie A, Hopital Cochin, Paris Cedex 14, France, ⁶Rheumatology, Paris Descartes University, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with an excess of mortality. This risk depends on the disease activity, severity and associated comorbidities. Our objective was…
Abstract Number: 557 • 2016 ACR/ARHP Annual Meeting
Differences in Clinical Outcomes in Different Socio-Economic and Racial Groups with Rheumatoid Arthritis: Data from National Inpatient Sample
Dilli Poudel¹, Rashmi Dhital², Abdullateef Abdulkareem³, Pragya Shrestha⁴ and Paras Karmacharya¹, ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Universal College of Medical Sciences, MBBS, Kathmandu, Nepal, ³Inernal Medicine, Reading Health System, West Reading, PA, ⁴Internal medicine, Reading Health System, West Reading, PA
Background/Purpose: Studies have reported differences in healthcare utilization and outcome among different socioeconomic and ethnic groups. Complications like atherosclerotic cardiovascular diseases (ASCVD) have been documented…
Abstract Number: 847 • 2016 ACR/ARHP Annual Meeting
Forced Vital Capacity Predicts Lung Fibrosis Progression and Mortality in Systemic Sclerosis
Anna Hoffmann-Vold¹, Elizabeth R. Volkmann², Oyvind Midtvedt³, Torhild Garen³, Anders Heiervang Tennøe³, Trond Mogens Aalokken⁴, May Brit Lund⁵ and Øyvind Molberg³, ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Respiratory Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but there are no valid methods for early detection of SSc-ILD or…
Abstract Number: 910 • 2016 ACR/ARHP Annual Meeting
Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study
Amar Oza¹, Na Lu² and Hyon K. Choi³, ¹Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Boston, MA, ²Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Recent studies have shown an increase in cardiovascular and all-cause mortality in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).1 The hypothesized dual role of…
Abstract Number: 42 • 2015 ACR/ARHP Annual Meeting
Does the Risk of Mortality in Patients with RA Change over Time or Disease Duration?
Kaleb Michaud^1,2, Sofia Pedro², Bryant R. England³ and Frederick Wolfe², ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Observational studies have shown an increased risk of mortality in patients with RA, though none have done so with patients from all 50 US…
Abstract Number: 223 • 2015 ACR/ARHP Annual Meeting
Increased Platelet Reactivity in Gout: A Potential Mechanism for Adverse Cardiovascular Events
Richard Conway¹, Claire-Louise Murphy², Anne Madigan², Patricia Kavanagh², Liz Geraghty², Laura Helbert², Kelly Stephens³, John J. Carey⁴, Eimear Dunne⁵, Dermot Kenny⁵ and Geraldine M. McCarthy⁶, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 2, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Mater Misericordiae University Hospital, Clinical Research Center, Dublin, Ireland, ⁴Rheumatology, Galway University Hospitals, Galway, Ireland, ⁵Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁶University College Dublin, Dublin, Ireland
Background/Purpose: Patients with inflammatory arthritis, including gout, have an increased risk of cardiovascular events and mortality. Increased platelet reactivity is a risk marker for cardiovascular…
Abstract Number: 826 • 2015 ACR/ARHP Annual Meeting
Systemic Sclerosis Inpatient Mortality Has Not Improved from 1995-2011. Results from a National Irish Audit of Scleroderma Co-Morbidities.
Len Harty¹, Deirdre Fitzgerald², Michael Henry², John Ryan³ and Sinead Harney³, ¹Cork University Hospital, Cork, Ireland, ²Respiratory, Cork University Hospital, Cork, Ireland, ³Rheumatology, Cork University Hospital, Cork, Ireland
Background/Purpose: Despite the advent of potent immunosuppressive and vasoactive therapies it is not clear that longevity of patients with systemic sclerosis (SSc) has improved. Therefore…
Abstract Number: 877 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Granulomatosis with Polyangiitis: A Population-Based Study
Ju Ann¹, Hyon K. Choi², Sharan K. Rai³, Eric C. Sayre⁴ and J Antonio Avina-Zubieta^5,6, ¹Experimental Mediine, University of British Columbia, Richmond, BC, Canada, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Richmond, BC, Canada, ⁵Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ⁶Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is associated with an increased risk of mortality. However, recent mortality trends in GPA are largely unknown, particularly in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].